News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Oxford Immunotec Limited Completes First Stage in 40 Million Funding Round
October 29, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Thomson Financial) - Prelude Trust PLC said its portfolio company Oxford Immunotec has completed the first stage of a new 40 mln usd series 'E' funding round.
Twitter
LinkedIn
Facebook
Email
Print
Startups
Europe
MORE ON THIS TOPIC
Drug Pricing
BMS, Pfizer Join DTC Trend, Offering Eliquis to Patients for 40% Below List Price
July 17, 2025
·
2 min read
·
Nick Paul Taylor
Layoffs
Sarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic
July 17, 2025
·
1 min read
·
Heather McKenzie
IN PARTNERSHIP WITH IQVIA
AI Is Taking Over Drug Safety Monitoring–But There’s One Thing It Can’t Replace
July 17, 2025
·
1 min read
·
Lori Ellis
Tariffs
Novartis ‘Moving as Fast as Possible’ to Fully Manufacture Key Drugs in US as Tariffs Near
July 17, 2025
·
2 min read
·
Tristan Manalac
